Skip to Content

'
Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.

Present Title & Affiliation

Primary Appointment

Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Program, Houston, TX

Education & Training

Degree-Granting Education

1999 The University of Texas Graduate School of Biomedical Sciences, Houston, TX, PHD, Cancer Biology
1989 Wakayama Medical College, Wakayama,, Japan, MD, Doctor of Medicine

Postgraduate Training

7/1993-6/1996 Clinical Fellowship, Medical Oncology and Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1991-6/1993 Clinical Residency, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
7/1990-6/1991 Clinical Internship, Internal Medicine, Montefiore University Hospital - University of Pittsburgh, Pittsburgh, PA
4/1989-3/1990 Clinical Internship, Rotating Internship, United States Naval Hospital, Yokosuka, Kanagawa, Japan

Board Certifications

1995 American Board of Internal Medicine - Medical Oncology
1993 American Board of Internal Medicine - Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125(3):785-95, 2/2011. e-Pub 12/9/2010. PMID: 21153052.
2. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7(11):641-51, 11/2010. e-Pub 8/31/2010. PMID: 20808302.
3. Ueno NT, Ito TD, Grigsby RK, Black MV, Apted J. ABC conceptual model of effective multidisciplinary cancer care. Nat Rev Clin Oncol 7(9):544-7, 9/2010. e-Pub 7/6/2010. PMID: 20603648.
4. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16(6):1802-11, 3/15/2010. e-Pub 3/9/2010. PMID: 20215547.
5. Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol 7(3):127-8, 3/2010. PMID: 20190792.
6. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15(21):6639-48, 11/2009. e-Pub 10/2009. PMCID: PMC2783487.
7. Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt Iii RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer 9(3):173-7, 8/2009. PMID: 19661041.
8. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10(6):606-14, 6/2009. PMID: 19482249.
9. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and [18 F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J Clin Oncol 27(27). e-Pub 5/2009. PMID: 19451443.
10. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 6(7). e-Pub 5/2009. PMID: 19468291.
11. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant 44(2). e-Pub 5/2009. PMID: 19448681.
12. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res 11(1). e-Pub 2/2009. PMID: 19239702.
13. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 68(22):9311-17, 11/2008. PMID: 19010903.
14. Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nature Clinical Practice Oncology 5(2):78-89, Jan-Feb, 2/2008. PMID: 18235440.
15. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Seminars In Oncology 35(1):64-71, Jan-Feb, 2/2008. PMID: 18308147.
16. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics 7(7):1846-50, 2008. PMID: 18644997.
17. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 67(12):5779-88, 6/2007. PMID: 17575145.
18. Itamochi H, Kigawa J, Kanamori Y, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Molecular Cancer Therapy 6:227-235, 2007.
19. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 110(7):1436-1444, 2007. PMID: 17694554.
20. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of Breast Cancer Cells to Erlotinib Depends on Cyclin-Dependent Kinase 2 Activity. Molecular Cancer Therapeutics 6(8):2168-2177, 2007. PMID: 17671085.
21. Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondon G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant 37:929-35, 5/2006. PMID: 16565737.
22. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25(1):79-90, 1/2006. PMID: 16170361.
23. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 65(18):8406-13, 9/2005. PMID: 16166319.
24. Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol Cancer Ther 4(7):1039-46, 7/2005. PMID: 16020661.
25. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942-53, 7/2004. PMID: 15254062.
26. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64(7):2502-8, 4/2004. PMID: 15059905.
27. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 62(22):6712-6, 11/2002. PMID: 12438271.
28. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7(12):4008-12, 12/2001. PMID: 11751494.
29. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14):3422-33, 7/2001. PMID: 11454891.
30. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 6(1):250-9, 2000. PMID: 10656456.
31. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16(3):986-93, 3/1998. PMID: 9508181.
32. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15(8):953-60, 8/1997. PMID: 9285690.

Editorials
1. Ueno NT, Shpall EJ, Champlin RE, Jones, RB. Graft-vs-Breast Cancer Effect by Allogeneic Hematopoietic Stem Cell Transplantation: A Possible New Frontier. J Clin Oncol 22:3846-3847, 2004.

Grant & Contract Support

Title: Academy of Cancer Expert (ACE)
Funding Source: AstraZeneca Medical Education Grants Office
Role: Principal Investigator
Duration: 7/1/2008 - 6/30/2009

Last updated: 10/3/2011